ArticleThe Journal of urology2012

Re: phase 1 and 2 studies demonstrate the safety and efficacy of intraprostatic injection of PRX302 for the targeted treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia.

No numbers read from the abstract.

Not cited yet